格隆汇1月12日丨迪哲医药(688192.SH)公布，经财务部门初步测算，预计2025年度实现营业收入80,000 万元左右，比上年同期增加44,010万元左右，同比增加122.28%左右。 预计2025年度归属于母公司所有者的净亏损77,000万元左右，比上年同期减少亏损7,596万元左右，同比 亏损减少8.98%左右。 预计2025年度归属于母公司所有者的扣除非经常性损益后的净亏损85,000万元左右，比上年同期减少亏 损4,889万元左右，同比亏损减少5.44%左右。 预计公司2025年度研发费用为86,000万元左右，比上年同期增加13,631万元左右，同比增加18.84%左 右。 ...

Financial Projections - The company expects to achieve approximately CNY 800 million in revenue for 2025, an increase of about CNY 440.1 million or 122.28% year-on-year[3]. - The estimated R&D expenses for 2025 are around CNY 860 million, an increase of approximately CNY 136.31 million or 18.84% year-on-year[3]. - The net loss attributable to the parent company is projected to be around CNY 770 million, a reduction of approximately CNY 75.96 million or 8.98% year-on-year[3]. - The net loss attributable to the parent company, excluding non-recurring gains and losses, is expected to be about CNY 850 million, a decrease of approximately CNY 48.89 million or 5.44% year-on-year[3]. - The company anticipates continued negative net profit due to high R&D investments, despite significant revenue growth and successful product development[7]. - There are no major uncertainties affecting the accuracy of this performance forecast[8]. Product Development and Approvals - The company has successfully included two products, Shuwozhe® and Gaoruizhe®, in the national medical insurance drug list, which is expected to significantly enhance patient accessibility and market share[4]. - Shuwozhe® received FDA approval for treating adult patients with locally advanced or metastatic NSCLC with EGFR Exon20ins mutations, marking it as the first and only EGFR Exon20ins NSCLC innovative drug approved in the U.S.[5]. - The company is actively advancing its core R&D products, including Shuwozhe® and Gaoruizhe®, with ongoing clinical studies presented at major international conferences[6]. - The company’s wholly-owned subsidiary obtained a drug production license, ensuring qualifications for future commercial production[7].

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 迪哲医药(688192.SH)公告称，迪哲医药发布2025年度业绩预告，预计归属于母公司所有者的净亏损7.7 亿元左右，较上年同期减少亏损约7,596万元。报告期内，公司两款获批产品舒沃哲和高瑞哲纳入国家 医保药品目录，推动产品销售收入增长至约8亿元，同比增长122.28%。 ...

Core Viewpoint - Dige Pharmaceutical (688192.SH) expects significant growth in revenue and a reduction in net losses for the fiscal year 2025, indicating a positive outlook for the company's financial performance [1] Financial Performance - The company anticipates a revenue of approximately 800 million yuan for 2025, an increase of about 440.1 million yuan compared to the previous year, representing a year-on-year growth of approximately 122.28% [1] - The projected R&D expenses for 2025 are around 860 million yuan, which is an increase of about 136.31 million yuan from the previous year, reflecting a year-on-year increase of approximately 18.84% [1] Net Losses - The expected net loss attributable to the parent company's shareholders for 2025 is around 770 million yuan, which is a reduction of approximately 75.96 million yuan compared to the previous year, indicating a year-on-year decrease in losses of about 8.98% [1] - The projected net loss attributable to the parent company after excluding non-recurring gains and losses is approximately 850 million yuan, which is a decrease of about 48.89 million yuan from the previous year, showing a year-on-year reduction in losses of approximately 5.44% [1]

Core Viewpoint - The company expects a revenue of approximately 800 million yuan for the fiscal year 2025, representing a year-on-year increase of 122.28%, primarily due to the inclusion of two approved products in the medical insurance and increased promotion efforts [1] Financial Performance - The projected R&D expenses are 860 million yuan, reflecting a year-on-year increase of 18.84%, indicating that the company's ongoing projects are progressing well with multiple clinical data announcements [1] - The expected net loss attributable to the parent company is 770 million yuan, which is a year-on-year decrease of 8.98%, while the net loss after excluding non-recurring items is projected at 850 million yuan, a year-on-year decrease of 5.44% [1] Product Development - The company has made significant progress in its research and development pipeline, with several projects announcing clinical data and some products receiving relevant FDA recognition and commencing clinical studies [1]

中访网数据 迪哲（江苏）医药股份有限公司于2026年1月9日召开2026年第一次临时股东会，会议审议 并通过了多项重要议案。核心决策包括批准公司发行H股股票并在香港联合交易所主板上市的相关方 案，以及为配合上市而进行的公司章程修订、注册资本变更等事宜。根据议案，公司本次H股发行的具 体方案涵盖上市地点、发行方式、规模、对象、定价原则等要素，发行决议有效期及相关授权也获得通 过。会议同时通过了发行前滚存利润分配方案、聘请上市审计机构、在香港进行公司注册并设立主要营 业地址等配套议案。此外，股东会还通过了关于改选公司独立董事及调整董事会专门委员会委员的议 案。本次股东会出席股东所持表决权数量占公司总表决权数量的64.4445%，各项议案均获得高票通 过，其中涉及H股发行及章程修订等8项议案作为特别决议案，均获出席股东所持表决权的三分之二以 上同意。此次股东会决议为公司推进香港上市计划奠定了关键的法律与决策基础，标志着其国际化资本 战略迈出重要一步。 来源：中访网 ...

二〇二六年一月 北京市中伦律师事务所 关于迪哲（江苏）医药股份有限公司 2026 年第一次临时股东会的 法律意见书 北京市中伦律师事务所 关于迪哲（江苏）医药股份有限公司 2026 年第一次临时股东会的 法律意见书 致：迪哲（江苏）医药股份有限公司 根据迪哲（江苏）医药股份有限公司（以下简称"公司"）与北京市中伦律 师事务所（以下简称"本所"）签订的《常年法律服务协议》的约定及受本所指 派，本所律师对公司 2026 年第一次临时股东会（以下简称"本次股东会"）的 合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委 员会（以下简称"中国证监会"）《上市公司股东会规则》（以下简称"《股东 会规则》"）等现行有效的有关法律、法规和规范性文件以及《迪哲（江苏）医 药股份有限公司章程》（以下简称"《公司章程》"）的规定而出具。 本所律师根据法律的要求，按照律师行业公认的业务标准、道德规范和勤勉 尽责的精神，对公司所提供的相关文件和有关事实进行了核查和验证，现出具法 律意见如下： 一、本次股东会的召集 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2026-001 迪哲（江苏）医药股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 9 日 （二） 股东会召开的地点：无锡市新吴区新阳路 50 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 97 | | --- | --- | | 普通股股东人数 | 97 | | 2、出席会议的股东所持有的表决权数量 | 297,210,231 | | 普通股股东所持有表决权数量 | 297,210,231 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 64.4445 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.4445 | （四） 表决方式是否符合《公司 ...

1月9日，迪哲医药涨5.2%，截至发稿，报66.75元/股，成交2.41亿元，换手率0.81%，总市值307.84亿 元。 资料显示，迪哲(江苏)医药股份有限公司位于江苏省无锡市新吴区和风路26号汇融商务广场C栋404、 405、416室,中国(上海)自由贸易试验区亮景路199、245号4幢，成立日期2017年10月27日，上市日期 2021年12月10日，公司主营业务涉及创新药物的研发和产业化,高度重视员工的创新研发能力。主营业 务收入构成为：销售药品100.00%。 从基金十大重仓股角度 数据显示，同泰基金旗下1只基金重仓迪哲医药。同泰大健康主题混合A（011002）三季度持有股数3.76 万股，占基金净值比例为5.41%，位居第五大重仓股。根据测算，今日浮盈赚取约12.42万元。 同泰大健康主题混合A（011002）成立日期2021年4月8日，最新规模1375.12万。今年以来收益7.74%， 同类排名577/8827；近一年收益25.89%，同类排名4600/8084；成立以来亏损50.98%。 同泰大健康主题混合A（011002）基金经理为马毅、麦健沛。 截至发稿，马毅累计任职时间11年299天，现 ...

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]